Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice

Molecular Therapy

Volumn 17, Issue 2, 2009, Pages 278-284

  Sallinen, Hanna ^a,b   Anttila, Maarit ^a,b   Narvainen, Johanna ^a   Koponen, Jonna ^a   Hamalainen, Kirsi ^a,b   Kholova, Ivana ^a,b   Heikura, Tommi ^a   Toivanen, Pyry ^a   Kosma, Veli Matti ^a,b   Heinonen, Seppo ^a,b   Alitalo, Kari ^c   Yla Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AGENTS ACTING ON THE GENITAL SYSTEM; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; SOLUBLE VASCULOTROPIN RECEPTOR 1; SOLUBLE VASCULOTROPIN RECEPTOR 2; SOLUBLE VASCULOTROPIN RECEPTOR 3; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; SURVIVAL TIME; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENE VECTOR; GENETICS; METHODOLOGY; NUDE MOUSE; OVARY TUMOR; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOVIRIDAE; MUS; TROPAEOLUM TUBEROSUM;

ANIMALS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 63649107910     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.258     Document Type: Article

References (38)

1. Jemal, A, Tiwari, RC, Murray, T, Ghafoor, A, Samuels, A, Ward, E et al. (2004). Cancer statistics, 2004. CA Cancer J Clin 54: 8-29.
2. Zeimet, AG and Marth, C (2003). Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 4: 415-422.
3. Folkman, J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
4. Dvorak, HF (2002). Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380.
5. Yamamoto, S, Konishi, I, Mandai, M, Kuroda, H, Komatsu, T, Nanbu, K et al. (1997). Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76: 1221-1227.
6. Sowter, HM, Corps, AN, Evans, AL, Clark, DE, Charnock-Jones, DS and Smith, SK (1997). Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 77: 607-614.
7. Yokoyama, Y, Charnock-Jones, DS, Licence, D, Yanaihara, A, Hastings, JM, Holland, CM et al. (2003). Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 88: 237-244.
8. Nishida, N, Yano, H, Komai, K, Nishida, T, Kamura, T and Kojiro, M (2004). Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 101: 1364-1374.
9. Olsson, AK, Dimberg, A, Kreuger, J and Claesson-Welsh, L (2006). VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
10. Takahashi, H and Shibuya, M (2005). The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109: 227-241.
11. Shibuya, M (2006). Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39: 469-478.
12. He, Z, Evelhoch, JL, Mohammad, RM, Adsay, NV, Pettit, GR, Vaitkevicius, VK et al. (2000). Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer. Pancreas 21: 69-76.
13. Kendall, RL, Wang, G and Thomas, KA (1996). Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226: 324-328.
14. Lin, P, Sankar, S, Shan, S, Dewhirst, MW, Polverini, PJ, Quinn, TQ et al. (1998). Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9: 49-58.
15. Millauer, B, Longhi, MP, Plate, KH, Shawver, LK, Risau, W, Ullrich, A et al. (1996). Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56: 1615-1620.
16. Makinen, T, Jussila, L, Veikkola, T, Karpanen, T, Kettunen, MI, Pulkkanen, KJ et al. (2001). Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 7: 199-205.
17. Sallinen, H, Anttila, M, Narvainen, J, Orden, MR, Ropponen, K, Kosma, VM et al. (2006). A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. Gynecol Oncol 103: 315-320.
18. Takei, Y, Mizukami, H, Saga, Y, Yoshimura, I, Hasumi, Y, Takayama, T et al. (2007). Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. Int J Cancer 120: 278-84.
19. Nagy, JA, Masse, EM, Herzberg, KT, Meyers, MS, Yeo, KT, Yeo, TK et al. (1995). Pathogenesis of ascites tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55: 360-368.
20. Hasumi, Y, Mizukami, H, Urabe, M, Kohno, T, Takeuchi, K, Kume, A et al. (2002). Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 62: 2019-2023.
21. Wu, Y, Li, ZY, Zhao, X, Kan, B and Wei, YQ (2006). Inhibition of ovarian tumor growth by gene therapy with recombinant soluble vascular endothelial growth factor receptor 2. Hum Gene Ther 17: 941-948.
22. Karkkainen, MJ, Saaristo, A, Jussila, L, Karila, KA, Lawrence, EC, Pajusola, K et al. (2001). A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA 98: 12677-12682.
23. Mahasreshti, PJ, Kataram, M, Wang, MH, Stockard, CR, Grizzle, WE, Carey, D et al. (2003). Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 9: 2701-2710.
24. Versnel, MA, Haarbrink, M, Langerak, AW, de Laat, PA, Hagemeijer, A, van der Kwast, TH et al. (1994). Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. Cancer Genet Cytogenet 73: 60-4.
25. Gilad, AA, Israely, T, Dafni, H, Meir, G, Cohen, B, Neeman, M (2005). Functional and molecular mapping of uncoupling between vascular permeability and loss of vascular maturation in ovarian carcinoma xenografts: The role of stroma cells in tumor angiogenesis. Int J Cancer 117: 202-211.
26. Aghajanian, C (2006). The role of bevacizumab in ovarian cancer - an evolving story. Gynecol Oncol 102: 131-133.
27. Byrne, AT, Ross, L, Holash, J, Nakanishi, M, Hu, L, Hofmann, JI et al. (2003). Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9: 5721-5728.
28. Wedge, SR, Kendrew, J, Hennequin, LF, Valentine, PJ, Barry, ST, Brave, SR et al. (2005). AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65: 4389-400.
29. Hurteau, JA, Blessing, JA, DeCesare, SL, Creasman, WT (2001). Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: A gynecologic oncology group study. Gynecol Oncol 82: 7-10.
30. Eisen, T, Boshoff, C, Mak, I, Sapunar, F, Vaughan, MM, Pyle, L et al. (2000). Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82 812-817.
31. Bhardwaj, S, Roy, H, Karpanen, T, He, Y, Jauhiainen, S, Hedman, M et al. (2005). Periadventitial angiopoietin-1 gene transfer induces angiogenesis in rabbit carotid arteries. Gene Ther 12: 388-394.
32. Pajusola, K, Aprelikova, O, Armstrong, E, Morris, S and Alitalo, K (1993). Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene 8: 2931-2937.
33. Takayama, K, Ueno, H, Nakanishi, Y, Sakamoto, T, Inoue, K, Shimizu, K et al. (2000). Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 60: 2169-2177.
34. Roy, H, Bhardwaj, S, Babu, M, Jauhiainen, S, Herzig, KH, Bellu, AR et al. (2005). Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Hum Gene Ther 16: 1422-1428.
35. Veikkola, T, Jussila, L, Makinen, T, Karpanen, T, Jeltsch, M, Petrova, TV et al. (2001). Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20: 1223-1231.
36. Laitinen, M, Makinen, K, Manninen, H, Matsi, P, Kossila, M, Agrawal, RS et al. (1998). Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther 9: 1481-1486.
37. Puumalainen, AM, Vapalahti, M, Agrawal, RS, Kossila, M, Laukkanen, J, Lehtolainen, P et al. (1998). β-Galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 9: 1769-1774.
38. Yla-Herttuala, S, Rosenfeld, ME, Parthasarathy, S, Glass, CK, Sigal, E, Witztum, JL et al. (1990). Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci USA 87: 6959-6963.